A biotech running its first trial can usually manage the budget with a spreadsheet and one person who knows where everything stands. That works fine until the second study starts, then a third, and suddenly the same person is tracking multiple site networks and payment schedules with tools only ever built for one study at a time.
Why this transition is harder than it looks
Budget knowledge concentrates in one person by default. Efficient at small scale, this becomes a single point of failure as study count grows if that person is unavailable, the institutional knowledge goes with them.
Spreadsheets fail quietly, not cleanly. A spreadsheet built for one study gets copied and adapted for each new one, gradually diverging in small ways that are hard to notice until numbers stop reconciling across studies.
There's rarely a dedicated finance function yet. Larger sponsors have teams focused specifically on trial budgets. A growing biotech often has clinical operations, finance, and the CEO all touching the same process without a clear owner.
Milestone payment approval becomes a bottleneck. When one person manages all payments across a growing portfolio, every approval routes through them, and delays start affecting site relationships exactly when they matter most for enrollment.
Cash forecasting gets harder exactly when it matters more. A growing portfolio with studies at different stages creates cash flow patterns much harder to forecast manually, right as board reporting and fundraising pressure increases.
Investor and board reporting exposes the gaps. A budget process never designed for consolidated, auditable reporting suddenly has to produce it, and stitching that together manually under a deadline creates avoidable stress.
What breaks first as a biotech scales
| Pain Point |
At One Study |
At Three or More |
| Budget knowledge |
Manageable |
Single point of failure |
| Tracking |
One spreadsheet |
Multiple diverging spreadsheets |
| Finance ownership |
Absorbed by ops |
Needs a clearer process |
| Payment approvals |
Quick |
Bottlenecked |
| Cash forecasting |
Straightforward |
Hard to predict manually |
| Board reporting |
Simple |
Requires manual consolidation |
Why this matters under ICH E6(R3)
Sponsor oversight responsibilities apply regardless of company size. A growing biotech still needs a defensible audit trail even while its internal process is still maturing.
How Cloudbyz CTFM approaches this
Cloudbyz CTFM is built to give a growing biotech a structured budget process from the start. Budgets, invoices, and payment status live in one system, and the Financial Navigator can answer plain-English status questions without one person holding it all from memory.
See how Cloudbyz CTFM supports growing biotechs scaling their study portfolio book a demo with your own study data.
Meeting at SCOPE Summit Europe? Our CEO, Dinesh Kashyap, will be in Barcelona on 13–14 October book time to talk this through.
